News

Daily Isometric Ritual Helping Thousands Naturally Overcome Chronic Knee Pain Without Pills, Surgery, or Equipment—Rooted in ...
Swiss pharma major Novartis has discontinued development of its experimental treatment QUC398 for knee osteoarthritis, ending ...
Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis ...
DelveInsight's “Musculoskeletal Pain Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth ...
Market OverviewThe Global Osteoarthritis Pain Drugs Market is valued at USD 10.32 Billion in 2023 and is projected to reach a value of USD 17.96 Billion by 2032 at a CAGR (Compound Annual Growth Rate) ...